Skip to main content

Advertisement

SpringerLink
Log in

Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours

  • Topic paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Upper urinary tract urothelial carcinoma (UTUC) shares many similarities with bladder-UC, but there is strong evidence on a clinical, aetiological, epidemiological and genetic level that key differences exist. In this review, we aim to highlight how UTUC differs from bladder-UC and report on the utility of molecular markers in the diagnosis and management of UTUC.

Materials and methods

A systematic literature search was conducted using the Medline and Embase databases and specific keyword combinations: ‘urothelial carcinoma’, ‘bladder cancer’, ‘transitional cell carcinoma’, ‘upper tract’, ‘upper urinary tract’, ‘genetics’, ‘prognosis’ and ‘biomarkers’.

Results

UTUC has specific acquired (e.g. Balkans nephropathy, phenacetin abuse) and genetic hereditary non-polyposis colorectal cancer risk factors compared with bladder-UC. In general, the molecular biology of UC is broadly similar, irrespective of location in the urinary tract. However, there are distinct genetic (microsatellite instability) and epigenetic (hypermethylation) differences between some UTUC and bladder-UC. Clinical-pathological variables (e.g. hydronephrosis, tumour architecture, tumour location, stage and grade) have independent predictive power in UTUC, but tissue and urinary biomarkers can improve the clinical prediction of recurrence, invasion and survival in UTUC, though the evidence level is weak.

Conclusions

UTUC shares many similarities with bladder-UC, but there is strong evidence that they should be considered as distinct urothelial entities. Prospective multi-institutional studies investigating molecular markers are urgently needed to augment clinic-pathological predictors in UTUC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mazeman E (1976) Tumours of the upper urinary tract calyces, renal pelvis and ureter. Eur Urol 2:120–126

    PubMed  CAS  Google Scholar 

  2. Raman JD, Messer J, Sielatycki JA et al (2011) Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int 107:1059–1064

    Article  PubMed  Google Scholar 

  3. Roupret M, Zigeuner R, Palou J et al (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 59:584–594

    Article  PubMed  Google Scholar 

  4. Habuchi T, Takahashi R, Yamada H et al (1993) Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342:1087–1088

    Article  PubMed  CAS  Google Scholar 

  5. Sidransky D, Frost P, Von Eschenbach A et al (1992) Clonal origin bladder cancer. N Engl J Med 326:737–740

    Article  PubMed  CAS  Google Scholar 

  6. Amar AD, Das S (1985) Upper urinary tract transitional cell carcinoma in patients with bladder carcinoma and associated vesicoureteral reflux. J Urol 133:468–471

    PubMed  CAS  Google Scholar 

  7. Hafner C, Knuechel R, Stoehr R et al (2002) Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 101:1–6

    Article  PubMed  CAS  Google Scholar 

  8. Jones TD, Wang M, Eble JN et al (2005) Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 11:6512–6519

    Article  PubMed  CAS  Google Scholar 

  9. Catto JW, Miah S, Owen HC et al (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69:8472–8481

    Article  PubMed  CAS  Google Scholar 

  10. Colin P, Koenig P, Ouzzane A et al (2009) Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 104:1436–1440

    Article  PubMed  CAS  Google Scholar 

  11. Grollman AP, Shibutani S, Moriya M et al (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104:12129–12134

    Article  PubMed  CAS  Google Scholar 

  12. McCredie M, Stewart JH, Day NE (1993) Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer 53:245–249

    Article  PubMed  CAS  Google Scholar 

  13. Roupret M, Yates DR, Comperat E et al (2008) Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol 54:1226–1236

    Article  PubMed  Google Scholar 

  14. Catto JW, Azzouzi AR, Amira N et al (2003) Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 22:8699–8706

    Article  PubMed  CAS  Google Scholar 

  15. Catto JW, Azzouzi AR, Rehman I et al (2005) Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23:2903–2910

    Article  PubMed  CAS  Google Scholar 

  16. Catto JW, Hartmann A, Stoehr R et al (2006) Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol 175:2323–2330

    Article  PubMed  CAS  Google Scholar 

  17. Catto JW, Yates DR, Rehman I et al (2007) Behavior of urothelial carcinoma with respect to anatomical location. J Urol 177:1715–1720

    Article  PubMed  CAS  Google Scholar 

  18. Shariat SF, Karakiewicz PI, Palapattu GS et al (2006) Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 12:6663–6676

    Article  PubMed  Google Scholar 

  19. Lughezzani G, Burger M, Margulis V et al (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114

    Article  PubMed  Google Scholar 

  20. Eltz S, Comperat E, Cussenot O et al (2008) Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int 102:532–535

    Article  PubMed  CAS  Google Scholar 

  21. Park J, Ha SH, Min GE et al (2009) The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol 182:894–899

    Article  PubMed  Google Scholar 

  22. van der Poel HG, Antonini N, van Tinteren H et al (2005) Upper urinary tract cancer: location is correlated with prognosis. Eur Urol 48:438–444

    Article  PubMed  Google Scholar 

  23. Shariat SF, Bolenz C, Karakiewicz PI et al (2010) p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int 105:489–495

    Article  PubMed  Google Scholar 

  24. Zigeuner R, Tsybrovskyy O, Ratschek M et al (2004) Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 63:1079–1083

    Article  PubMed  Google Scholar 

  25. Mitchell S, Mayer E, Patel A (2011) Expression of p53 in upper urinary tract urothelial carcinoma. Nat Rev Urol 8:516–522

    Article  PubMed  CAS  Google Scholar 

  26. Nakanishi K, Tominaga S, Hiroi S et al (2002) Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch 441:559–563

    Article  PubMed  CAS  Google Scholar 

  27. Jeong IG, Kim SH, Jeon HG et al (2009) Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol 40:668–677

    Article  PubMed  CAS  Google Scholar 

  28. Ke HL, Chang LL, Yang SF et al (2011) Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol 29:703–709

    Article  PubMed  CAS  Google Scholar 

  29. Jeon HG, Jeong IG, Bae J et al (2010) Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology 76:513.e7–513.e12

    Article  Google Scholar 

  30. Joung JY, Yang SO, Jeong IG et al (2008) Identification of immunohistochemical factors that predict the synchronous or metachronous development of bladder tumors in patients with upper urinary tract tumors. Urol Int 81:306–311

    Article  PubMed  CAS  Google Scholar 

  31. Leibl S, Zigeuner R, Hutterer G et al (2008) EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS 116:27–32

    Article  PubMed  Google Scholar 

  32. Yeh HC, Huang CH, Yang SF et al (2010) Nuclear factor-kappaB activation predicts an unfavourable outcome in human upper urinary tract urothelial carcinoma. BJU Int 106:1223–1229

    Article  PubMed  Google Scholar 

  33. Langner C, Gross C, Rehak P et al (2005) HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique. Urology 65:176–180

    Article  PubMed  Google Scholar 

  34. Vershasselt-Crinquette M, Colin P, Ouzzane A et al (2012) Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry. Appl Immunohistochem Mol Morphol 20:363–366

    Article  PubMed  CAS  Google Scholar 

  35. Inoue K, Kamada M, Slaton JW et al (2002) The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 8:1863–1870

    PubMed  CAS  Google Scholar 

  36. Fromont G, Roupret M, Amira N et al (2005) Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol 48:764–770

    Article  PubMed  CAS  Google Scholar 

  37. Nakanishi K, Kawai T, Torikata C et al (1997) E-cadherin expression in upper-urinary-tract carcinoma. Int J Cancer 74:446–449

    Article  PubMed  CAS  Google Scholar 

  38. Miyata Y, Kanda S, Nomata K et al (2004) Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival. Urology 63:602–608

    Article  PubMed  Google Scholar 

  39. Ohtsuka Y, Kawakami S, Fujii Y et al (2006) Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int 97:1322–1326

    Article  PubMed  Google Scholar 

  40. Kosaka T, Kikuchi E, Mikami S et al (2010) Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Clin Cancer Res 16:5814–5823

    Article  PubMed  CAS  Google Scholar 

  41. Nakanishi K, Kawai T, Hiroi S et al (1999) Expression of telomerase mRNA component (hTR) in transitional cell carcinoma of the upper urinary tract. Cancer 86:2109–2116

    Article  PubMed  CAS  Google Scholar 

  42. Nakanishi K, Hiroi S, Tominaga S et al (2005) Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res 11:2583–2590

    Article  PubMed  CAS  Google Scholar 

  43. Miyazaki Y, Kosaka T, Mikami S et al (2012) The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res 18:4145–4153

    Article  PubMed  CAS  Google Scholar 

  44. Saito K, Kawakami S, Ohtsuka Y et al (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 100:269–273

    Article  PubMed  CAS  Google Scholar 

  45. Suyama T, Nakajima K, Kanbe S et al (2011) Prognostic significance of preoperative serum CYFRA 21–1 in patients with upper urinary tract urothelial carcinoma. Int J Urol 18:43–47

    Article  PubMed  CAS  Google Scholar 

  46. Lehmann J, Suttmann H, Kovac I et al (2007) Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol 51:1281–1288

    Article  PubMed  Google Scholar 

  47. Akkad T, Brunner A, Pallwein L et al (2007) Fluorescence in situ hybridization for detecting upper urinary tract tumors—a preliminary report. Urology 70:753–757

    Article  PubMed  Google Scholar 

  48. Mian C, Mazzoleni G, Vikoler S et al (2010) Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours. Eur Urol 58:288–292

    Article  PubMed  Google Scholar 

  49. Huang WT, Li LY, Pang J et al (2012) Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology. Neoplasma 59:355–360

    Article  PubMed  CAS  Google Scholar 

  50. Jovanovic M, Soldatovic I, Janjic A et al (2011) Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors. Urol Int 87:134–137

    Article  PubMed  CAS  Google Scholar 

  51. Ho CL, Tzai TS, Chen JC et al (2008) The molecular signature for urothelial carcinoma of the upper urinary tract. J Urol 179:1155–1159

    Article  PubMed  CAS  Google Scholar 

  52. van Oers JM, Zwarthoff EC, Rehman I et al (2009) FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 55:650–657

    Article  PubMed  Google Scholar 

  53. Roupret M, Drouin SJ, Cancel-Tassin G et al (2012) Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. J Urol 187:424–428

    Article  PubMed  CAS  Google Scholar 

  54. Roupret M, Cancel-Tassin G, Comperat E et al (2007) Phenol sulfotransferase SULT1A1*2 allele and enhanced risk of upper urinary tract urothelial cell carcinoma. Cancer Epidemiol Biomarkers Prev 16:2500–2503

    Article  PubMed  CAS  Google Scholar 

  55. Zhang Z, Furge KA, Yang XJ et al (2010) Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics 3:58

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. The Academic Department of Urology, Royal Hallamshire Hospital, Glossop Rd, Sheffield, UK

    David R. Yates & James W. F. Catto

Authors
  1. David R. Yates
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James W. F. Catto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David R. Yates.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yates, D.R., Catto, J.W.F. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours. World J Urol 31, 21–29 (2013). https://doi.org/10.1007/s00345-012-0946-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-012-0946-6

Keywords

Search

Navigation